The massive dilution relative to market cap (137.5% of current equity) and the warrant overhang (up to 4.4M additional shares) create significant downward pressure on the stock. Traders should expect continued weakness as the tranches close and warrants become exercisable. Monitor for shareholder vote on warrant issuance and any updates on IND-enabling studies for AKTX-101.
Price Chart
Executive Summary
Akari Therapeutics announced a private placement raising approximately $5.5 million through the sale of 1,470,588 ADSs at $3.74 per ADS, along with Series H, I, and J warrants exercisable for additional shares. The funds will support the lead ADC program AKTX-101 toward a Phase 1 trial expected to start by mid-2027. The offering is structured in three tranches closing between May 27 and July 15, 2026, and the warrants require shareholder approval.
Key Financial Metrics
Key Facts
- Gross proceeds of approximately $5.5 million from the private placement.
- 1,470,588 ADSs sold at $3.74 per ADS, representing a discount to the current market price.
- Series H, I, and J warrants each exercisable for 1,470,588 ADSs at $3.74 per ADS, with terms of 18 months (Series H) and 60 months (Series I and J).
- Warrant issuance is subject to shareholder approval.
- Proceeds will be used for working capital and general corporate purposes.
- Offering is structured in three tranches with closings expected between May 27, 2026 and July 15, 2026.
- Company has a market cap of $4 million, making the $5.5 million raise highly dilutive relative to current equity.
Financial Impact
The $5.5 million raise represents approximately 137.5% of the current $4 million market cap, indicating severe dilution. The warrants, if exercised, could add up to 4,411,764 additional shares, further diluting existing holders.
Risk Factors
- Severe dilution from the offering and potential warrant exercise.
- Warrant overhang could cap any upside for months.
- Company is pre-revenue with no approved products; cash runway remains limited.
- Shareholder approval required for warrant issuance adds execution risk.
- Clinical-stage biotech with no near-term catalyst until mid-2027 Phase 1 start.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299304 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.58 (+13.79%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.58 (+36.07%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.58 (−39.62%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.58 (+17.58%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.58 (−61.09%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.58 (+51.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers